Logo

AMRN

Amarin Corporation plc

AMRN

Amarin Corporation plc • NASDAQ
$15.97 ▼ -1.05% (-0.17)
Market Cap $330.30 M
52w High $20.90
52w Low $7.00
Dividend Yield 0%
P/E -3.8
Volume 47.14K
Outstanding Shares 20.68M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $48.558M ▼ $23.905M ▼ $-7.738M ▲ -15.936% ▲ $-0.02 ▲ $-6.494M ▼
Q2-2025 $72.741M ▲ $66.347M ▲ $-14.139M ▲ -19.437% ▲ $-0.03 ▲ $7.503M ▲
Q1-2025 $42.017M ▼ $41.885M ▼ $-15.697M ▲ -37.359% ▲ $-0.8 ▼ $-16.025M ▲
Q4-2024 $62.306M ▲ $42.955M ▲ $-48.618M ▼ -78.031% ▼ $-0.12 ▼ $-37.181M ▼
Q3-2024 $42.298M $41.444M $-25.134M -59.421% $-0.061 $-24.415M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $286.587M ▼ $659.814M ▼ $200.92M ▼ $458.894M ▼
Q2-2025 $298.704M ▲ $670.126M ▲ $205.202M ▲ $464.924M ▼
Q1-2025 $281.787M ▼ $655.677M ▼ $181.99M ▼ $473.687M ▼
Q4-2024 $294.22M ▼ $685.349M ▼ $199.173M ▼ $486.176M ▼
Q3-2024 $305.732M $750.615M $219.24M $531.375M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.692M ▲ $-12.763M ▼ $-12.295M ▼ $-239.995K ▲ $-25.074M ▼ $-12.763M ▼
Q2-2025 $-14.139M ▲ $16.606M ▲ $12.41M ▲ $-663K ▲ $28.353M ▲ $16.606M ▲
Q1-2025 $-15.697M ▲ $-12.459M ▲ $12.064M ▲ $-1.119M ▼ $-1.514M ▲ $-12.459M ▲
Q4-2024 $-48.167M ▼ $-13.243M ▼ $-22.754M ▲ $22.955K ▲ $-36.132M ▲ $-13.243M ▼
Q3-2024 $-25.392M $-2.435M $-56.665M $-74.126K $-58.979M $-2.435M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Licensing And Royalty
Licensing And Royalty
 $0 ▲$0 ▲$30.00M ▲$0 ▼
Product
Product
 $60.00M ▲$40.00M ▼$50.00M ▲$50.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Amarin’s income statement shows a company in transition. Sales have trended down over the last few years, reflecting pressure in its core U.S. market from generic competition. The business has moved from a brief period of slight profitability back into operating losses, meaning current revenues are not yet covering the full cost base. Gross profit is still positive, which shows the product itself can be sold at a healthy spread over direct costs, but that spread is shrinking and overhead remains heavy relative to sales. Overall, recent results reflect a company tightening its belt while trying to rebuild growth, with profitability fragile and highly sensitive to even small changes in revenue or costs.

Balance Sheet

Balance Sheet The balance sheet looks relatively clean but gradually weaker. Amarin carries very little financial debt, which reduces refinancing and interest risk. It still has a meaningful cash cushion, but that cash balance has been trending down as losses and negative cash flow accumulate. Total assets and shareholder equity have also slipped over time, signaling that the company is slowly drawing on its financial reserves. There is no sign of immediate balance sheet stress, but the direction of travel suggests that restoring sustainable profitability and cash generation will be important to avoid further erosion of its financial base over the medium term.

Cash Flow

Cash Flow Cash flow paints the same picture as the income statement: the core business is close to break-even but not consistently there. Operating cash flow has hovered around zero, with mildly positive and negative years, indicating that day‑to‑day operations are not yet providing a steady source of cash. Capital spending is minimal, so free cash flow largely mirrors operating cash flow. This means that small swings in working capital, pricing, or spending discipline can tip the company into either modest cash burn or slight cash generation. Over time, repeated small outflows can add up, so the path back to stable, positive operating cash flow is a key issue.

Competitive Edge

Competitive Edge Amarin’s competitive position is highly concentrated but still distinctive. The company effectively revolves around one flagship product, Vascepa/Vazkepa, which has strong clinical data in cardiovascular risk reduction and a differentiated scientific profile compared with standard fish oil supplements. That evidence base and physician familiarity are important strengths. However, in the United States, generic versions have sharply reduced Amarin’s pricing power and revenue opportunity, weakening its moat. In contrast, Europe offers a more favorable environment, with long-dated patent protection and regulatory support that can limit direct competition there for many years. Manufacturing complexity and product purity add some barriers to entry, but heavy reliance on a single drug and exposure to reimbursement decisions remain core competitive risks.

Innovation and R&D

Innovation and R&D Innovation at Amarin is focused and relatively narrow, built around icosapent ethyl and cardiovascular disease. The company’s major trial data and ongoing analyses reinforce the scientific credibility of its core product and help maintain interest among specialists. Its move toward fixed-dose combination therapies – potentially pairing its drug with other heart medicines in a single pill – could refresh the product story and extend its life if clinical and regulatory outcomes are favorable. At the same time, the pipeline appears concentrated rather than broad; there are no obvious, unrelated new product families to diversify risk. Cost-cutting efforts must be balanced against the need to keep investing in meaningful new studies, combinations, and geographies so innovation does not stall.

Summary

Amarin today is a focused, single-product cardiovascular company grappling with the fallout from U.S. generic competition while trying to unlock value in international markets. Financially, revenues and profitability have weakened, cash burn is modest but persistent, and the balance sheet, while still solid, is slowly being drawn down. Competitively, the story is split: the U.S. is mature and pressured, whereas Europe and other ex‑U.S. regions offer a longer runway thanks to strong patents, regulatory support, and partnerships. The company’s scientific foundation is strong, but its dependence on one main asset heightens both risk and upside: execution in Europe, success of partnering strategies, and progress on combination products will likely be the main forces shaping Amarin’s trajectory from here, with significant uncertainty around how quickly it can convert these opportunities into stable, profitable growth.

NEWS

November 9, 2025 · 4:15 PM UTC

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Read more

November 3, 2025 · 8:30 AM UTC

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Read more

October 14, 2025 · 8:00 AM UTC

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Read more

August 31, 2025 · 8:30 AM UTC

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Read more

August 30, 2025 · 8:30 AM UTC

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Read more